Screener
Sarepta Therapeutics, Inc. SRPT Business Segments — Other Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Manufacturing expenses | 1,837 | 80,685 | 21,595 | 148,150 |
| Clinical trial expenses | 23,102 | 33,511 | 41,406 | 66,658 |
| Facility- and technology-related expenses (excluding depreciation and amortization) | 23,890 | 28,580 | 46,832 | 56,237 |
| Research and development- other (excluding non-cash items) (1) | 19,847 | 31,843 | 38,518 | 60,314 |
| Selling, general and administrative- other (excluding non-cash items) (2) | 42,462 | 56,322 | 82,655 | 107,464 |
| Roche collaboration reimbursement | (7,169) | (25,689) | (15,358) | (54,170) |
| Other segment items (3) | (709) | (1,314) | (2,515) | (3,223) |
| Loss (gain) on strategic investments | 448 | (36,721) | 2,160 | 54,007 |
Item 1. Financial Statements
FAQ
- What is Sarepta Therapeutics, Inc.'s business segments — other research and development expense?
- Sarepta Therapeutics, Inc. (SRPT) reported business segments — other research and development expense of $19.85M in Q2 2026.
- How has Sarepta Therapeutics, Inc.'s business segments — other research and development expense changed year-over-year?
- Sarepta Therapeutics, Inc.'s business segments — other research and development expense decreased by 37.7% year-over-year, from $31.84M to $19.85M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s business segments — other research and development expense?
- Over 3 years (2022 to 2025), Sarepta Therapeutics, Inc.'s business segments — other research and development expense has grown at a -2.9% compound annual growth rate (CAGR), from $117.17M to $107.35M.
- What does business segments — other research and development expense mean?
- Encompasses miscellaneous research and development expenditures not captured in specific clinical trial categories, such as early-stage discovery or platform research. It tracks the ongoing investment in the segment's long-term innovation capabilities.
Ask your AI about Sarepta Therapeutics, Inc.'s business segments — other research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude